The role of alloantibodies against human platelet antigen‐15 in multiply platelet transfused patients

Matsuhashi, Mika; Tsuno, Nelson H.; Sone, Satoru; Mishima, Yuko; Nagura, Yutaka; Watanabe‐Okochi, Naoko; Ikeda, Toshiyuki; Kashiwase, Koichi; Fukuda, Seiichi; Iriyama, Takayuki; Hyodo, Hideo; Yamashita, Takahiro; Kamei, Yoshimasa; Arai, Shunya; Minami, Manabu; Fujii, Tomoyuku; Kurokawa, Mineo; Tozuka, Minoru; Takahashi, Koki

doi:10.1111/trf.12455

Cited by 16 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, this study is the first to focus on multiple HPA-15 compatible and incompatible transfusions to explore the impact of HPA-15 alloantibodies on PTR. In contrast to our conclusion, Matsuhashi et al 12 demonstrated possible involvement of HPA-15b antibodies on PTR in one HPA-15-incompatible platelet transfusion. In their study, one more HPA-15 incompatible transfusion was performed, which resulted in a high CCI.…”

Section: Discussioncontrasting

confidence: 99%

Minor impact of patient alloantibodies against human platelet antigen (HPA)‐15 in the effectiveness of platelet transfusion: A pilot study

et al. 2020

View full text Add to dashboard Cite

Background Alloantibodies against human platelet antigen (HPA)‐15 are sometimes detected in patients with platelet transfusion refractoriness (PTR); however, little is known about their impact on PTR. Study Design and Methods Two patients who possessed HPA‐15 alloantibodies (Patient 1, anti‐HPA‐15b; Patient 2, anti‐HPA‐15a) and human leukocyte antigen (HLA) antibodies were enrolled. The efficacy of HPA‐15–compatible vs –incompatible platelet transfusion was compared by focusing on ABO‐ and HLA‐matched transfusions on the basis of the 24‐hour corrected count increment (CCI‐24 hours) for platelets. The titers of HPA‐15 antibodies in the patients' sera were also monitored. Results The patients received 71 and 12 ABO‐compatible, HLA‐matched platelet transfusions, respectively, during the monitoring periods. Among these transfusions, CCI‐24 hours could be calculated in 27 and 10 transfusions, respectively, and the HPA‐15 genotype of the donors was determined. There were no significant differences in the CCI‐24 hours between the HPA‐15 compatible and incompatible transfusions in both patients (P = .30 and .56, respectively, Mann‐Whitney U test). There was no significant change in the HPA‐15b antibody titer in Patient 1 during the monitoring period, while the HPA‐15a antibody level in Patient 2 was undetectable at the end of the monitoring period, although the titer was low at the beginning. Conclusion The efficacy of HPA‐15–incompatible platelet transfusions was not necessarily inferior to that of HPA‐15 compatible ones. Although the case number was limited, our results suggest that HPA‐15 antibodies do not have a significant impact on the effects of platelet transfusion.

show abstract

Section: Discussioncontrasting

confidence: 99%

Minor impact of patient alloantibodies against human platelet antigen (HPA)‐15 in the effectiveness of platelet transfusion: A pilot study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We conclude from our analysis that BBA can be considered a helpful initial screening tool in the PLT serology laboratory since analysis is fast and overall test specificity is very good. Major drawbacks of this method include 1) inadequate sensitivity for some specificities, which will require appropriate algorithms in the laboratory to avoid the release of false‐negative results, and 2) nonavailability of beads for the detection of HPA‐15 antibodies, which are relevant in causing FNAIT and PLT transfusion refractoriness, necessitating the use of additional testing.…”

Section: Discussionmentioning

confidence: 99%

A bead‐based assay in the work‐up of suspected platelet alloimmunization

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ethnical variabilities of HPA frequency distribution As described above, the HPA systems involved in NAIT vary between Caucasian and Japanese, the HPA-1 system being predominant in the former and the HPA-4 system in the latter. As shown in Table 2 [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49], presently, there are reports on the frequency distribution of HPAs from different Asian countries, and although differences exist, it seems that the HPA-1 system, like in Japan, is not important in the majority of them. On the other hand, the HPA-4 system, which is important in Japan, is also relevant in South Korea and possibly Indonesia (2 contradictory reports), but not in the other countries.…”

Section: Treatmentmentioning

confidence: 99%

The importance of platelet antigens and antibodies in immune‐mediated thrombocytopenia

Tsuno

Matsuhashi

Iino

et al. 2014

ISBT Science Series

View full text Add to dashboard Cite

Platelet antigens/antibodies play an important role in immune mediated-thrombocytopenia. Here, we review the clinical conditions associated with anti-platelet alloantibodies, giving special emphasis to the differences in human platelet antigen (HPA) frequency distribution between Caucasian and Asian populations. Also, we describe the presently available methods for the detection of anti-platelet alloantibodies, and the activities of the International Society of Blood Transfusion (ISBT) Platelet Immunology Working Parties, which play an active role in the exchange of information and materials among the labs involved in platelet immunobiology research worldwide, and have significantly contributed for the development of this field.

show abstract

The role of alloantibodies against human platelet antigen‐15 in multiply platelet transfused patients

Abstract: In this study, we found alloimmunization against HPA-15a and -15b in Japanese populations and demonstrated the relevance of these antibodies in a patient with PTR.

Cited by 16 publications

References 32 publications

Minor impact of patient alloantibodies against human platelet antigen (HPA)‐15 in the effectiveness of platelet transfusion: A pilot study

Minor impact of patient alloantibodies against human platelet antigen (HPA)‐15 in the effectiveness of platelet transfusion: A pilot study

A bead‐based assay in the work‐up of suspected platelet alloimmunization

The importance of platelet antigens and antibodies in immune‐mediated thrombocytopenia

Contact Info

Product

Resources

About